Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer by Ottley, EC, Pell, R, Brazier, B, Hollidge, J, Kartsonaki, C, Browning, L, O'Neill, E, Kiltie, A

VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer by Redchenko, I, Cappuccini, F, Pollock, E, Bryant, R, Carter, L, Verrill, C, Hollidge, J, Goodwin, L, Harrop, R, Romero, P, Vigano, S, Evans, T, Catto, J, Hamdy, F, Hill, A

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: A phase I clinical trial by Cappuccini, F, Bryant, R, Pollock, E, Carter, L, Verrill, C, Hollidge, J, Poulton, I, Baker, M, Mitton, C, Baines, A, Meier, A, Schmidt, G, Harrop, R, Protheroe, A, MacPherson, R, Kennish, S, Morgan, S, Vigano, S, Romero, PJ, Evans, T, Catto, J, Freddie Hamdy, Hill, AVS, Redchenko, I